Capecitabine: 5 agencies, 2000–2018
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 17.9 years separate the first record, 16 Nov 2000 at PHARMAC (New Zealand), from the most recent, 3 Oct 2018 at HAS (France).
PHARMAC (New Zealand) changed its position: not recommended on 16 Nov 2000, recommended by 12 Nov 2009, after a resubmission.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2018; on this evidence the file is dormant.
5 distinct indication wordings are recorded for capecitabine by the agencies that label one in English (AWMSG, NICE and SMC).
PHARMAC (New Zealand) was first to assess capecitabine, on 16 Nov 2000; NICE (England) did not open a file until 28 Jul 2010 — an unusually long tail of 9.7 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 8 years in total.
4 of the 5 agencies here assessed capecitabine more than once, PHARMAC (New Zealand) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed capecitabine.
The full ledger for capecitabine reads 8 recommended, 3 other, 1 deferred to NICE and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 3 Oct 2018 | Listing renewal (Transparency Committee) | SMR substantial | source |
| NICE (England) | 28 Jul 2010 | NICE TA191 | recommended | source |
| AWMSG (Wales) | 12 Nov 2008 | TA191: Capecitabine for the treatment of advanced gastric cancer | excluded, NICE appraised | source |
| SMC (Scotland) | 7 Mar 2003 | Metastatic breast cancer | unknown | source |
| PHARMAC (New Zealand) | 16 Nov 2000 | Locally advanced or metastatic breast cancer after failure of two prior chemotherapeutic regimes | PTAC advice: Decline · decision reached | source |
8 further decisions for capecitabine, across 4 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- pemetrexed — same ATC class L01B — Antineoplastics
- azacitidine — same ATC class L01B — Antineoplastics
- gemcitabine — same ATC class L01B — Antineoplastics
- cytarabine — same ATC class L01B — Antineoplastics
- fluorouracile — same ATC class L01B — Antineoplastics
- clofarabine — same ATC class L01B — Antineoplastics
Coverage: 13 decisions for capecitabine from 5 agencies, 2000 to 2018. Data to 7 Sep 2026. ATC class L01B — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.